Theravance Biopharma, Inc. (TBPH) is a publicly traded company in the Unknown sector. Across all available filings, 38 corporate insiders have executed 586 transactions totaling $36.6M, demonstrating a bullish sentiment with $10.5M in net insider flow. The most recent transaction on Feb 20, 2026 involved a transaction of 20,833 shares valued at $409.6K.
No significant insider buying has been recorded for TBPH in the recent period.
No significant insider selling has been recorded for TBPH in the recent period.
Based on recent SEC filings, insider sentiment for TBPH is bullish with an Insider Alignment Score of 64/100 and a net flow of $10.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Theravance Biopharma, Inc. (TBPH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 38 insiders are actively trading TBPH stock, having executed 586 transactions in the past 90 days. The most active insider is Plc Gsk (Executive), who has made 1 transactions totaling $94.0M.
Get notified when executives and directors at TBPH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | A. Grimaud Brett | SVP, GEN COUNSEL AND SECRETARY | Payment | 20,833 | $19.66 | $409.6K | |
| Feb 20, 2026 | Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | Payment | 16,851 | $19.66 | $331.3K | |
| Feb 20, 2026 | Sawaf Aziz | SVP & CHIEF FINANCIAL OFFICER | Payment | 20,672 | $19.66 | $406.4K | C-Suite |
| Feb 20, 2026 | E. Winningham Rick | Executive | Payment | 74,975 | $19.66 | $1.5M | Large |
| Dec 3, 2025 | Farnum Rhonda | Executive | Sale | 15,534 | $18.75 | $291.3K | |
| Dec 3, 2025 | Farnum Rhonda | Executive | Sale | 7,767 | $18.75 | $145.6K | |
| Dec 3, 2025 | Farnum Rhonda | Executive | Sale | 7,766 | $18.75 | $145.6K | |
| Nov 26, 2025 | Broshy Eran | Executive | Sale | 14,000 | $20.00 | $280.0K | |
| Nov 26, 2025 | Broshy Eran | Executive | Sale | 15,501 | $20.00 | $310.0K | |
| Nov 20, 2025 | E. Winningham Rick | Executive | Payment | 56,817 | $17.90 | $1.0M | Large |
| Nov 20, 2025 | Farnum Rhonda | Executive | Payment | 9,060 | $17.90 | $162.2K | |
| Nov 20, 2025 | A. Grimaud Brett | Executive | Payment | 19,024 | $17.90 | $340.5K | |
| Nov 20, 2025 | Miller Aine | Executive | Payment | 6,989 | $17.90 | $125.1K | |
| Nov 20, 2025 | Sawaf Aziz | Executive | Payment | 18,627 | $17.90 | $333.4K | |
| Nov 19, 2025 | E. Winningham Rick | Executive | Gift | 9,900 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Other(J) | 3 | $94.0M | 50.4% |
Payment(F) | 294 | $55.6M | 29.8% |
Purchase(P) | 18 | $23.6M | 12.6% |
Sale(S) | 67 | $13.0M | 7.0% |
Disposition(D) | 1 | $105.0K | 0.1% |
Award(A) | 195 | $69.2K | 0.0% |
Gift(G) | 7 | $0 | 0.0% |
Will Acquisition(W) | 1 | $0 | 0.0% |
Insiders at Theravance Biopharma, Inc. are accumulating shares at an accelerated pace. With 38 insiders making 586 transactions totaling $23.6M in purchases versus $13.0M in sales, the net buying activity of $10.5M signals strong executive confidence. Plc Gsk (Executive) leads the buying activity with $94.0M in transactions across all time.